Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Protein therapeutics
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Takeda Pharmaceutical
Deal Size: $882.0 million Upfront Cash: $44.0 million
Deal Type: Collaboration March 26, 2020
Details:
Deal allows Evox to continue advancing its exosome-based targeting and delivery technology, while also leveraging Takeda’s development and clinical expertise to advance these partnered programmes.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ETX001
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2020
Details:
Paper demonstrates first in class TMEM16A chloride channel potentiators, to accelerate mucociliary clearance.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
